Novartis is partnering with Bicycle Therapeutics to see if the biotech’s technology can be used to develop better, more targeted radiopharmaceuticals. The deal covers two targets that were not disclosed.
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
AstraZeneca drug Imjudo is now FDA approved for treating advanced liver cancer. The infused therapy is administered under a novel dosing schedule in addition to Imfinzi, an AstraZeneca drug already approved for treating several different types of cancer.
AstraZeneca reported that its Covid-19 vaccine was 79% effective at preventing severe infection and 100% effective at preventing hospitalization. The company expects to file a submission seeking FDA emergency use authorization in coming weeks.
Reuters reported Wednesday that U.S. regulators would look at data from previous clinical trials that came from the same scientists who created the vaccine, AZD1222, which originated at the University of Oxford and is also known as ChAdOx1 nCoV-19.
A review published in JAMA found that bills introduced into the House and Senate don't go nearly as far as existing drug pricing regulations other countries. The researchers listed eight key lessons from six nations.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The drugmaker said Monday that it had obtained clearance from the U.K.'s drug regulator to continue studies of the vaccine, AZD1222, which it licensed from the University of Oxford. Additionally, Pfizer's CEO said in a televised interview that the company has a good chance of knowing by the end of October if its vaccine works.
The New York Times had reported that the participant in question was taking part in a Phase II/III trial in the U.K. The event was reported the same day that AstraZeneca's CEO and nine others signed a pledge not to rush development of vaccines against the SARS-CoV-2 virus.
The companies plan to enroll 440 healthy adult volunteers into the trial, which is taking place at 11 sites in the U.S. Data are expected in December, and if successful, they will launch a Phase III trial that same month.
The companies said Monday that they had launched the Phase II/III COMET-ICE trial of VIR-7831, which will enroll about 1,300 patients around the world and investigate the drug as a way to prevent hospitalization of high-risk individuals infected with SARS-CoV-2.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and health authorities in the U.S., is enrolling up to 48 healthy volunteers in the U.K. AstraZeneca's double-antibody approach is similar to that of Regeneron and Roche with their drug, REGN-COV2.
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu.
The company said that patients receiving the drug, SNG001, had a 79% lower risk of requiring ventilation or dying compared with those on placebo, sending the company's stock soaring more than 400%, but it did not clarify what that meant in terms of patient numbers.